CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 14 enrolled
Drug / intervention
MagVenture MagPro Transcranial Magnetic Stimulation (TMS) Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05878457
NCT05878457Phase 1Completed

Accelerated rTMS for Post-Stroke Apathy: Targeting Amotivation Toward Improving Whole Health and Rehabilitation Engagement

Medical University of South Carolina·interventional·Posted May 26, 2023·Updated Jun 12, 2025

In Brief

A Phase 1 clinical trial evaluating MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System for Apathy and 5 related conditions. Completed, enrolled 14 participants across 1 site.

Detailed Summary

This pilot study will investigate the safety, feasibility, tolerability, and preliminary efficacy of accelerated high-dose repetitive transcranial magnetic stimulation (rTMS) targeting the medial prefrontal cortex (mPFC) to address apathy symptoms in individuals with chronic stroke.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
202420252026
First PostedMay 26, 2023
Enrollment StartDec 1, 2023
Primary CompletionApr 30, 2025
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 3.1 years ago

Interventions

MagVenture MagPro Transcranial Magnetic Stimulation (TMS) Systemdevice

Treatment will consist 12 approximately-three-minute sessions on each of three treatment days within a seven-day period. To promote participant adherence and retention, treatment days will not need to be contiguous. A single session consists of 600 pulses delivered to the dmPFC at an intensity of 120% resting motor threshold (rMT). 50 hz triphasic bursts will be delivered for two seconds, followed by an 8 second inter-train interval. Trains will be repeated every 10 seconds, 10 times total, for a total of 190 seconds per session. An intersession interval of at least 15 minutes will be employed between each of the 12 sessions. Each treatment day will thus last approximately 3-4 hours in duration.